Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder

Dario Arnaldi, Andrea Chincarini, Michele T Hu, Karel Sonka, Bradley Boeve, Tomoyuki Miyamoto, Monica Puligheddu, Valérie Cochen De Cock, Michele Terzaghi, Giuseppe Plazzi, Naoko Tachibana, Silvia Morbelli, Michal Rolinski, Petr Dusek, Val Lowe, Masayuki Miyamoto, Michela Figorilli, Delphine de Verbizier, Irene Bossert, Elena Antelmi, Riccardo Meli, Thomas R Barber, Jiří Trnka, Toji Miyagawa, Alessandra Serra, Fabio Pizza, Matteo Bauckneht, Kevin M Bradley, David Zogala, Daniel R McGowan, Lennon Jordan, Raffaele Manni, Flavio Nobili, Dario Arnaldi, Andrea Chincarini, Michele T Hu, Karel Sonka, Bradley Boeve, Tomoyuki Miyamoto, Monica Puligheddu, Valérie Cochen De Cock, Michele Terzaghi, Giuseppe Plazzi, Naoko Tachibana, Silvia Morbelli, Michal Rolinski, Petr Dusek, Val Lowe, Masayuki Miyamoto, Michela Figorilli, Delphine de Verbizier, Irene Bossert, Elena Antelmi, Riccardo Meli, Thomas R Barber, Jiří Trnka, Toji Miyagawa, Alessandra Serra, Fabio Pizza, Matteo Bauckneht, Kevin M Bradley, David Zogala, Daniel R McGowan, Lennon Jordan, Raffaele Manni, Flavio Nobili

Abstract

This is an international multicentre study aimed at evaluating the combined value of dopaminergic neuroimaging and clinical features in predicting future phenoconversion of idiopathic REM sleep behaviour (iRBD) subjects to overt synucleinopathy. Nine centres sent 123I-FP-CIT-SPECT data of 344 iRBD patients and 256 controls for centralized analysis. 123I-FP-CIT-SPECT images were semiquantified using DaTQUANTTM, obtaining putamen and caudate specific to non-displaceable binding ratios (SBRs). The following clinical variables were also analysed: (i) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale, motor section score; (ii) Mini-Mental State Examination score; (iii) constipation; and (iv) hyposmia. Kaplan-Meier survival analysis was performed to estimate conversion risk. Hazard ratios for each variable were calculated with Cox regression. A generalized logistic regression model was applied to identify the best combination of risk factors. Bayesian classifier was used to identify the baseline features predicting phenoconversion to parkinsonism or dementia. After quality check of the data, 263 iRBD patients (67.6 ± 7.3 years, 229 males) and 243 control subjects (67.2 ± 10.1 years, 110 males) were analysed. Fifty-two (20%) patients developed a synucleinopathy after average follow-up of 2 years. The best combination of risk factors was putamen dopaminergic dysfunction of the most affected hemisphere on imaging, defined as the lower value between either putamina (P < 0.000001), constipation, (P < 0.000001) and age over 70 years (P = 0.0002). Combined features obtained from the generalized logistic regression achieved a hazard ratio of 5.71 (95% confidence interval 2.85-11.43). Bayesian classifier suggested that patients with higher Mini-Mental State Examination score and lower caudate SBR asymmetry were more likely to develop parkinsonism, while patients with the opposite pattern were more likely to develop dementia. This study shows that iRBD patients older than 70 with constipation and reduced nigro-putaminal dopaminergic function are at high risk of short-term phenoconversion to an overt synucleinopathy, providing an effective stratification approach for future neuroprotective trials. Moreover, we provide cut-off values for the significant predictors of phenoconversion to be used in single subjects.

Keywords: Parkinson’s disease; REM sleep behaviour disorder; SPECT; dementia with Lewy bodies.

© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Figures

Figure 1
Figure 1
Box plot of raw (A) and adjusted (B) DAT-SPECT data. Imaging data were adjusted by age, sex and centre. The x-axis shows DAT-SPECT specific to non-displaceable binding ratios (SBRs). The y-axis shows the centres involved in the study. LAH = least affected hemisphere; MAH = most affected hemisphere.
Figure 2
Figure 2
Disease free survival and hazard rate over time in iRBD patients. The left plot shows disease-free survival (i.e. free of parkinsonism and dementia) over time (years) in iRBD patients. The right plot shows the hazard rate over time (years) in iRBD patients computed on the exponential and Weibull survivor functions.
Figure 3
Figure 3
Kaplan-Meier disease-free survival plots for iRBD patients according to the best predictors of phenoconversion and the combined feature obtained by the generalized logistic regression.
Figure 4
Figure 4
Forest plot showing the risk factors’ HR. The lines show 95% confidence intervals. LAH = least affected hemisphere; MAH = most affected hemisphere.

Source: PubMed

3
구독하다